文献速递产科母胎医学

心脏病孕妇计划阴道分娩与心血管疾病发病率

Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease.
PubMed 文献 · Am J Obstet Gynecol · 2019-07-13

该前瞻性队列研究纳入2011年9月至2016年12月在学术性三级医疗中心分娩的276名心脏病孕妇,比较计划阴道分娩与计划剖宫产的心血管及产科不良结局。结果显示两组不良心脏结局相似(4.3% vs 3.0%,P=1.00),计划阴道分娩组产后出血(1.9% vs 10.6%,P<.01)和输血(1.9% vs 9.1%,P=.01)更低。结论提示剖宫产不减少心血管不良结局,支持多数心脏病孕妇计划阴道分娩。

要点

  • 计划阴道分娩组与计划剖宫产组不良心脏结局相似(4.3% vs 3.0%,P=1.00)。
  • 计划阴道分娩组产后出血(1.9% vs 10.6%,P<.01)和输血(1.9% vs 9.1%,P=.01)低于计划剖宫产组。
  • 本研究中心的做法是鼓励心脏病孕妇阴道分娩,除非有剖宫产产科指征。

核心结论

  • 研究结果提示剖宫产不减少心血管不良结局,支持多数心脏病孕妇(包括高危心脏病)计划阴道分娩。

研究设计与样本

  • 前瞻性队列研究,纳入2011年9月至2016年12月在学术性三级医疗中心分娩的276名心脏病孕妇,采用多学科方案化管理。
  • 按计划分娩方式分为计划阴道分娩组(76%,n=210)和计划剖宫产组(24%,n=66),采用单变量分析比较不良结局。

主要发现

  • 心脏病类型构成:先天性心脏病68.5%、心律失常11.2%、结缔组织病9.1%、心肌病8.0%、瓣膜病1.4%、血管性心脏病1.8%。
  • 计划阴道分娩组不良心脏结局4.3% vs 计划剖宫产组3.0%(P=1.00),差异无统计学意义。
  • 计划阴道分娩组产后出血1.9% vs 计划剖宫产组10.6%(P<.01),输血1.9% vs 9.1%(P=.01),计划阴道分娩组更低。
  • 计划阴道分娩者中86.2%(n=181)成功阴道分娩,阴道助产率9.5%;5例因心血管疾病指征(无其他产科指征)由分娩提供者决定行阴道助产,其中4例在分娩前耐受15至75分钟的Valsalva动作试验。
  • 整体队列及高危心血管疾病或高产科合并症负担亚组中,不良心脏、产科或新生儿结局均无差异。

关键数值与推荐

  • 本研究中心的做法是:除非有剖宫产产科指征,否则鼓励心脏病孕妇阴道分娩。
  • 本研究中心允许尝试阴道分娩的孕妇在第二产程行Valsalva动作试验,若用力导致血流动力学改变或症状,可行阴道助产。

临床怎么用

  • 本研究中心的做法是鼓励心脏病孕妇阴道分娩,除非有剖宫产产科指征;允许尝试阴道分娩者在第二产程行Valsalva动作试验,必要时行阴道助产。
  • 研究结果提示剖宫产不减少心血管不良结局,支持多数心脏病孕妇(包括高危心脏病)计划阴道分娩。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although consensus guidelines on the management of cardiovascular disease in pregnancy reserve cesarean delivery for obstetric indications, there is a paucity of data to support this approach. OBJECTIVE: The objective of the study was to compare cardiovascular and obstetric morbidity in women with cardiovascular disease according to the plan for vaginal birth or cesarean delivery. STUDY DESIGN: We assembled a prospective cohort of women delivering at an academic tertiary care center with a protocolized multidisciplinary approach to management of cardiovascular disease between September 2011 and December 2016. Our practice is to encourage vaginal birth in women with cardiovascular disease unless there is an obstetric indication for cesarean delivery. We allow women attempting vaginal birth a trial of Valsalva in the second stage with the ability to provide operative vaginal delivery if pushing leads to changes in hemodynamics or symptoms. Women were classified according to planned mode of delivery: either vaginal birth or cesarean delivery. We then used univariate analysis to compare adverse outcomes according to planned mode of delivery. The primary composite cardiac outcome of interest included sustained arrhythmia, heart failure, cardiac arrest, cerebral vascular accident, need for cardiac surgery or intervention, or death. Secondary obstetric and neonatal outcomes were also considered. RESULTS: We included 276 consenting women with congenital heart disease (68.5%), arrhythmias (11.2%), connective tissue disease (9.1%), cardiomyopathy (8.0%), valvular disease (1.4%), or vascular heart disease (1.8%) at or beyond 24 weeks' gestation. Seventy-six percent (n = 210) planned vaginal birth and 24% (n = 66) planned cesarean delivery. Women planning vaginal birth had lower rates of left ventricular outflow tract obstruction, multiparity, and preterm delivery. All women attempting vaginal birth were allowed Valsalva. Among planned vaginal deliveries 86.2% (n = 181) were successful, with a 9.5% operative vaginal delivery rate. Five women underwent operative vaginal delivery for the indication of cardiovascular disease without another obstetric indication at the discretion of the delivering provider. Four of these patients tolerated trials of Valsalva ranging from 15 to 75 minutes prior to delivery. Adverse cardiac outcomes were similar between planned vaginal birth and cesarean delivery groups (4.3% vs 3.0%, P = 1.00). Rates of postpartum hemorrhage (1.9% vs 10.6%, P < .01) and transfusion (1.9% vs 9.1%, P = .01) were lower in the planned vaginal birth group. There were no differences in adverse cardiac, obstetric, or neonatal outcomes in the cohort overall or the subset of women with high-risk cardiovascular disease or a high burden of obstetric comorbidity. CONCLUSION: These findings suggest that cesarean delivery does not reduce adverse cardiovascular outcomes and lend support to a planned vaginal birth for the majority of women with cardiovascular disease including those with high-risk disease.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Easter SR, Rouse CE, Duarte V, et al. Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease. Am J Obstet Gynecol. 2019. PMID: 31310750. doi:10.1016/j.ajog.2019.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。